1.Sales and profit
See section β- Werewolf Therapeutics, Inc. lost $60.8M in fiscal 2025.
Werewolf Therapeutics, Inc.
HOWL Nasdaq Pharmaceutical Preparations Financials FY2020βFY2025
Last close Β· Oct 23, 2026
$0.98
3.0%KIRAβs summary AI analyst
Hi! I read Werewolf Therapeutics, Inc.βs latest annual report (fiscal 2025). Here is what stands out:
1 strength 3 to watch
2.Cash and shareholders
See section β- Free cash flow was β$60.3M in fiscal 2025, β of revenue.
- In the last 12 months, insiders sold $6.6M of shares on the open market and bought none.
3.Financial health
See section β- Werewolf Therapeutics, Inc. has $25.0M more cash than debt.
- Werewolf Therapeutics, Inc. passes 1 of 7 financial health tests (Piotroski F-score).
Werewolf Therapeutics, Inc. in 30 seconds
Good So-so Weak
Weak
Does it make a profit?
β$60.8M
No. It lost money last year.
Weak
How healthy are the accounts?
1 / 7
Weak. It passes 1 of 7 health tests.
For information
How is the share priced?
β
No P/E: it made no profit over the last four quarters.
Rules of thumb on reported numbers. A starting point, not a recommendation.
Key numbers, fiscal 2025
Market cap
Last close times the latest diluted share count, so it is approximate.
$47.6M
Oct 23 close
P/E
Last close divided by diluted earnings per share over the last four quarters.
β
On β$0.73 EPS (TTM)
Charts by
Sales and profit
Is it selling more, and how much does it keep?
Revenue and margins
In plain words: Revenue is all the money customers paid. The margins show how many cents of each dollar of sales are left over at each step: after making the product (gross), after running the business (operating) and after everything, tax included (net).
Revenue
FY20
Revenue β
FY21
Revenue β
FY22
Revenue β
FY23
Revenue β
FY24
Revenue β
FY25
Revenue β
Margins, % of revenue
FY20
Gross β
Operating β
Net β
FCF β
FY21
Gross β
Operating β
Net β
FCF β
FY22
Gross β
Operating β
Net β
FCF β
FY23
Gross β
Operating β
Net β
FCF β
FY24
Gross β
Operating β
Net β
FCF β
FY25
Gross β
Operating β
Net β
FCF β
Gross
Operating
Net
FCF
Net income and earnings per share
KIRA Β· Werewolf Therapeutics, Inc. lost $60.8M in fiscal 2025.
Loss periods are shown in red.
In plain words: Net income is the profit left after every cost and tax. Earnings per share (EPS) splits that profit across every share, so it shows what one share earned.
Net income
FY20
Net income β$15.0M
FY21
Net income β$50.0M
FY22
Net income β$53.8M
FY23
Net income β$37.4M
FY24
Net income β$70.5M
FY25
Net income β$60.8M
Net income
Q3 '23
Net income β$8.3M
Q4 '23
Net income β$12.0M
Q1 '24
Net income β$16.2M
Q2 '24
Net income β$17.2M
Q3 '24
Net income β$16.7M
Q4 '24
Net income β$20.4M
Q1 '25
Net income β$18.1M
Q2 '25
Net income β$18.0M
Q3 '25
Net income β$16.4M
Q4 '25
Net income β$8.4M
Q1 '26
Net income β$13.5M
Q2 '26
Net income $3.7M
Diluted EPS
FY20
Diluted EPS β$28.08
FY21
Diluted EPS β$10.94
FY22
Diluted EPS β$1.86
FY23
Diluted EPS β$1.05
FY24
Diluted EPS β$1.63
FY25
Diluted EPS β$1.33
Diluted EPS
Q3 '23
Diluted EPS β$0.23
Q4 '23
Diluted EPS β$0.34
Q1 '24
Diluted EPS β$0.39
Q2 '24
Diluted EPS β$0.43
Q3 '24
Diluted EPS β$0.38
Q4 '24
Diluted EPS β$0.43
Q1 '25
Diluted EPS β$0.40
Q2 '25
Diluted EPS β$0.40
Q3 '25
Diluted EPS β$0.36
Q4 '25
Diluted EPS β$0.17
Q1 '26
Diluted EPS β$0.28
Q2 '26
Diluted EPS $0.08
Cash and shareholders
How much cash comes in, and where does it go?
Cash flow
KIRA Β· Free cash flow was β$60.3M in fiscal 2025, β of revenue.
Cash from operations minus capital spending.
In plain words: Profit on paper is not the same as cash in the bank. Free cash flow is the cash left after paying to run and maintain the business: the money it can hand back to shareholders, save or invest.
Free cash flow
FY20
Free cash flow β$19.2M
FY21
Free cash flow β$43.4M
FY22
Free cash flow β$44.2M
FY23
Free cash flow β$33.4M
FY24
Free cash flow β$56.4M
FY25
Free cash flow β$60.3M
Free cash flow
Q3 '23
Free cash flow β$7.4M
Q4 '23
Free cash flow β$4.8M
Q1 '24
Free cash flow β$15.4M
Q2 '24
Free cash flow β$14.2M
Q3 '24
Free cash flow β$12.5M
Q4 '24
Free cash flow β$14.4M
Q1 '25
Free cash flow β$18.9M
Q2 '25
Free cash flow β$15.2M
Q3 '25
Free cash flow β$15.2M
Q4 '25
Free cash flow β$11.0M
Q1 '26
Free cash flow β
Q2 '26
Free cash flow β
Cash from operations vs capital spending
FY20
Cash from operations β$18.6M
Capital spending $0.6M
FY21
Cash from operations β$42.9M
Capital spending $0.5M
FY22
Cash from operations β$40.6M
Capital spending $3.6M
FY23
Cash from operations β$32.6M
Capital spending $0.8M
FY24
Cash from operations β$56.2M
Capital spending $0.3M
FY25
Cash from operations β$60.3M
Capital spending $0.0M
Cash from operations
Capital spending
Cash from operations vs capital spending
Q3 '23
Cash from operations β$7.2M
Capital spending $0.2M
Q4 '23
Cash from operations β$4.6M
Capital spending $0.2M
Q1 '24
Cash from operations β$15.3M
Capital spending $0.1M
Q2 '24
Cash from operations β$14.2M
Capital spending $0.0M
Q3 '24
Cash from operations β$12.5M
Capital spending $0.0M
Q4 '24
Cash from operations β$14.3M
Capital spending $0.1M
Q1 '25
Cash from operations β$18.9M
Capital spending $0.0M
Q2 '25
Cash from operations β$15.2M
Capital spending $0.0M
Q3 '25
Cash from operations β$15.2M
Capital spending $0.0M
Q4 '25
Cash from operations β$11.0M
Capital spending $0.0M
Q1 '26
Cash from operations β$10.6M
Capital spending β
Q2 '26
Cash from operations $6.6M
Capital spending β
Cash from operations
Capital spending
Dividends, buybacks and share count
In plain words: Companies hand cash back in two ways: dividends (cash paid to shareholders) and buybacks (buying back their own shares, so each remaining share owns a bigger slice).
Dividends and buybacks
FY20
Dividends β
Buybacks β
FY21
Dividends β
Buybacks β
FY22
Dividends β
Buybacks β
FY23
Dividends β
Buybacks β
FY24
Dividends β
Buybacks β
FY25
Dividends β
Buybacks β
Dividends
Buybacks
Diluted shares outstanding (annual)
FY20
Diluted shares 0.00B
FY21
Diluted shares 0.02B
FY22
Diluted shares 0.03B
FY23
Diluted shares 0.04B
FY24
Diluted shares 0.04B
FY25
Diluted shares 0.05B
Insider trades
KIRA Β· In the last 12 months, insiders sold $6.6M of shares on the open market and bought none.
Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. βPlanβ marks trades under a pre-arranged Rule 10b5-1 plan.
In plain words: Insiders are the people who run or own a big part of the company. Buying with their own money can signal confidence; selling often has personal reasons, like taxes or diversifying.
Bought, 12 months
$0.0M
0 insiders
Sold, 12 months
$6.6M
10 insiders
Of sales under plans
85%
$5.7M
| Date | Insider | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Jul 7, 2026 | Luke EvninDirector | Sold plan | 107,429 | $0.31 | $0.0M | Form 4 |
| Jul 6, 2026 | Luke EvninDirector | Sold plan | 35,770 | $0.32 | $0.0M | Form 4 |
| Jun 29, 2026 | Luke EvninDirector | Sold plan | 157,084 | $0.30 | $0.0M | Form 4 |
| Jun 17, 2026 | Ra Capital Management, L.P.10% owner | Sold | 416,911 | $0.35 | $0.1M | Form 4 |
| Jun 16, 2026 | Ra Capital Management, L.P.10% owner | Sold | 149,625 | $0.37 | $0.1M | Form 4 |
| Jun 15, 2026 | Ra Capital Management, L.P.10% owner | Sold | 128,770 | $0.39 | $0.1M | Form 4 |
| Jun 12, 2026 | Ra Capital Management, L.P.10% owner | Sold | 170,441 | $0.40 | $0.1M | Form 4 |
| Jun 11, 2026 | Peter Kolchinsky10% owner | Sold | 262,503 | $0.38 | $0.1M | Form 4 |
| Jun 10, 2026 | Peter Kolchinsky10% owner | Sold | 45,923 | $0.37 | $0.0M | Form 4 |
| Jun 9, 2026 | Luke EvninDirector | Sold plan | 76,928 | $0.37 | $0.0M | Form 4 |
| Jun 9, 2026 | Peter Kolchinsky10% owner | Sold | 369,800 | $0.37 | $0.1M | Form 4 |
| Jun 8, 2026 | Luke EvninDirector | Sold plan | 60,547 | $0.40 | $0.0M | Form 4 |
| Jun 5, 2026 | Luke EvninDirector | Sold plan | 24,946 | $0.40 | $0.0M | Form 4 |
| Jun 4, 2026 | Luke EvninDirector | Sold plan | 20,072 | $0.44 | $0.0M | Form 4 |
| Jun 3, 2026 | Luke EvninDirector | Sold plan | 29,749 | $0.42 | $0.0M | Form 4 |
| Jun 2, 2026 | Luke EvninDirector | Sold plan | 29,595 | $0.45 | $0.0M | Form 4 |
| Jun 1, 2026 | Luke EvninDirector | Sold plan | 80,459 | $0.47 | $0.0M | Form 4 |
| May 29, 2026 | Luke EvninDirector | Sold plan | 32,556 | $0.45 | $0.0M | Form 4 |
| May 28, 2026 | Luke EvninDirector | Sold plan | 27,698 | $0.46 | $0.0M | Form 4 |
| May 27, 2026 | Luke EvninDirector | Sold plan | 80,852 | $0.48 | $0.0M | Form 4 |
| May 26, 2026 | Luke EvninDirector | Sold plan | 67,950 | $0.47 | $0.0M | Form 4 |
| May 22, 2026 | Luke EvninDirector | Sold plan | 87,425 | $0.45 | $0.0M | Form 4 |
| May 21, 2026 | Luke EvninDirector | Sold plan | 36,387 | $0.42 | $0.0M | Form 4 |
| May 20, 2026 | Luke EvninDirector | Sold plan | 85,895 | $0.43 | $0.0M | Form 4 |
| May 19, 2026 | Luke EvninDirector | Sold plan | 62,970 | $0.45 | $0.0M | Form 4 |
| May 18, 2026 | Luke EvninDirector | Sold plan | 22,184 | $0.50 | $0.0M | Form 4 |
| May 13, 2026 | Luke EvninDirector | Sold plan | 44,679 | $0.54 | $0.0M | Form 4 |
| May 12, 2026 | Luke EvninDirector | Sold plan | 67,885 | $0.64 | $0.0M | Form 4 |
| May 12, 2026 | Ra Capital Management, L.P.10% owner | Sold | 101,151 | $0.64 | $0.1M | Form 4 |
| May 11, 2026 | Luke EvninDirector | Sold plan | 33,948 | $0.67 | $0.0M | Form 4 |
| May 11, 2026 | Ra Capital Management, L.P.10% owner | Sold | 87,490 | $0.67 | $0.1M | Form 4 |
| May 8, 2026 | Luke EvninDirector | Sold plan | 305,741 | $0.70 | $0.2M | Form 4 |
| May 8, 2026 | Ra Capital Management, L.P.10% owner | Sold | 376,526 | $0.71 | $0.3M | Form 4 |
| May 7, 2026 | Luke EvninDirector | Sold plan | 79,086 | $0.63 | $0.0M | Form 4 |
| May 6, 2026 | Luke EvninDirector | Sold plan | 14,635 | $0.66 | $0.0M | Form 4 |
| May 5, 2026 | Luke EvninDirector | Sold plan | 6,860 | $0.69 | $0.0M | Form 4 |
| May 4, 2026 | Luke EvninDirector | Sold plan | 47,963 | $0.72 | $0.0M | Form 4 |
| May 1, 2026 | Luke EvninDirector | Sold plan | 58,394 | $0.73 | $0.0M | Form 4 |
| Apr 30, 2026 | Luke EvninDirector | Sold plan | 168,262 | $0.72 | $0.1M | Form 4 |
| Apr 29, 2026 | Luke EvninDirector | Sold plan | 56,559 | $0.69 | $0.0M | Form 4 |
| Apr 28, 2026 | Luke EvninDirector | Sold plan | 95,412 | $0.73 | $0.1M | Form 4 |
| Apr 27, 2026 | Luke EvninDirector | Sold plan | 53,940 | $0.85 | $0.0M | Form 4 |
| Jan 16, 2026 | Luke EvninDirector | Sold plan | 38,782 | $0.54 | $0.0M | Form 4 |
| Jan 15, 2026 | Luke EvninDirector | Sold plan | 37,413 | $0.55 | $0.0M | Form 4 |
| Jan 14, 2026 | Luke EvninDirector | Sold plan | 30,616 | $0.57 | $0.0M | Form 4 |
| Jan 13, 2026 | Luke EvninDirector | Sold plan | 43,198 | $0.55 | $0.0M | Form 4 |
| Jan 12, 2026 | Luke EvninDirector | Sold plan | 58,980 | $0.57 | $0.0M | Form 4 |
| Jan 9, 2026 | Luke EvninDirector | Sold plan | 24,678 | $0.61 | $0.0M | Form 4 |
| Jan 8, 2026 | Luke EvninDirector | Sold plan | 7,716 | $0.63 | $0.0M | Form 4 |
| Jan 7, 2026 | Luke EvninDirector | Sold plan | 11,915 | $0.64 | $0.0M | Form 4 |
| Jan 6, 2026 | Luke EvninDirector | Sold plan | 40,761 | $0.65 | $0.0M | Form 4 |
| Jan 5, 2026 | Luke EvninDirector | Sold plan | 18,378 | $0.64 | $0.0M | Form 4 |
| Jan 2, 2026 | Luke EvninDirector | Sold plan | 18,568 | $0.63 | $0.0M | Form 4 |
| Dec 31, 2025 | Luke EvninDirector | Sold plan | 24,962 | $0.62 | $0.0M | Form 4 |
| Dec 30, 2025 | Luke EvninDirector | Sold plan | 34,847 | $0.61 | $0.0M | Form 4 |
| Dec 29, 2025 | Luke EvninDirector | Sold plan | 108,606 | $0.61 | $0.1M | Form 4 |
| Dec 26, 2025 | Luke EvninDirector | Sold plan | 35,632 | $0.63 | $0.0M | Form 4 |
| Dec 24, 2025 | Luke EvninDirector | Sold plan | 16,310 | $0.65 | $0.0M | Form 4 |
| Dec 23, 2025 | Luke EvninDirector | Sold plan | 71,428 | $0.63 | $0.0M | Form 4 |
| Dec 22, 2025 | Luke EvninDirector | Sold plan | 59,307 | $0.69 | $0.0M | Form 4 |
| Dec 17, 2025 | Luke EvninDirector | Sold plan | 9,983 | $1.14 | $0.0M | Form 4 |
| Dec 16, 2025 | Luke EvninDirector | Sold plan | 14,548 | $1.05 | $0.0M | Form 4 |
| Dec 15, 2025 | Luke EvninDirector | Sold plan | 23,640 | $1.07 | $0.0M | Form 4 |
| Dec 12, 2025 | Luke EvninDirector | Sold plan | 17,858 | $1.08 | $0.0M | Form 4 |
| Dec 11, 2025 | Luke EvninDirector | Sold plan | 28,009 | $1.07 | $0.0M | Form 4 |
| Dec 10, 2025 | Luke EvninDirector | Sold plan | 37,104 | $1.06 | $0.0M | Form 4 |
| Dec 9, 2025 | Luke EvninDirector | Sold plan | 44,570 | $1.01 | $0.0M | Form 4 |
| Dec 8, 2025 | Luke EvninDirector | Sold plan | 34,041 | $0.99 | $0.0M | Form 4 |
| Dec 5, 2025 | Luke EvninDirector | Sold plan | 16,568 | $0.97 | $0.0M | Form 4 |
| Dec 4, 2025 | Luke EvninDirector | Sold plan | 53,416 | $0.97 | $0.1M | Form 4 |
| Dec 4, 2025 | MPM BioImpact LLCFormer 10% Owner | Sold plan | 83,230 | $0.97 | $0.1M | Form 4 |
| Dec 4, 2025 | MPM BioVentures 2014 (B), L.P.Former 10% Owner | Sold plan | 83,230 | $0.97 | $0.1M | Form 4 |
| Dec 3, 2025 | Luke EvninDirector | Sold plan | 36,726 | $0.87 | $0.0M | Form 4 |
| Dec 3, 2025 | MPM BioImpact LLCFormer 10% Owner | Sold plan | 57,225 | $0.87 | $0.0M | Form 4 |
| Dec 3, 2025 | MPM BioVentures 2014 (B), L.P.Former 10% Owner | Sold plan | 57,225 | $0.87 | $0.0M | Form 4 |
| Dec 2, 2025 | Luke EvninDirector | Sold plan | 38,043 | $0.89 | $0.0M | Form 4 |
| Dec 2, 2025 | MPM BioImpact LLCFormer 10% Owner | Sold plan | 59,277 | $0.89 | $0.1M | Form 4 |
| Dec 2, 2025 | MPM BioVentures 2014 (B), L.P.Former 10% Owner | Sold plan | 59,277 | $0.89 | $0.1M | Form 4 |
| Dec 1, 2025 | Luke EvninDirector | Sold plan | 39,096 | $0.94 | $0.0M | Form 4 |
| Dec 1, 2025 | UBS Oncology Impact Fund L.P.10% owner | Sold plan | 60,917 | $0.94 | $0.1M | Form 4 |
| Nov 28, 2025 | Luke EvninDirector | Sold plan | 13,014 | $0.99 | $0.0M | Form 4 |
| Nov 28, 2025 | UBS Oncology Impact Fund L.P.10% owner | Sold plan | 20,277 | $0.99 | $0.0M | Form 4 |
| Nov 26, 2025 | Luke EvninDirector | Sold plan | 38,978 | $0.98 | $0.0M | Form 4 |
| Nov 26, 2025 | UBS Oncology Impact Fund L.P.10% owner | Sold plan | 60,733 | $0.98 | $0.1M | Form 4 |
| Nov 25, 2025 | Luke EvninDirector | Sold plan | 27,297 | $0.92 | $0.0M | Form 4 |
| Nov 25, 2025 | MPM BioVentures 2014 GP LLC10% owner | Sold plan | 42,533 | $0.92 | $0.0M | Form 4 |
| Nov 24, 2025 | Luke EvninDirector | Sold plan | 56,992 | $0.98 | $0.1M | Form 4 |
| Nov 24, 2025 | MPM BioVentures 2014 GP LLC10% owner | Sold plan | 88,802 | $0.98 | $0.1M | Form 4 |
| Nov 21, 2025 | Luke EvninDirector | Sold plan | 41,287 | $0.83 | $0.0M | Form 4 |
| Nov 21, 2025 | MPM BioVentures 2014 GP LLC10% owner | Sold plan | 64,331 | $0.83 | $0.1M | Form 4 |
| Nov 20, 2025 | Luke EvninDirector | Sold plan | 26,411 | $0.89 | $0.0M | Form 4 |
| Nov 20, 2025 | MPM Oncology Innovations Fund GP LLC10% owner | Sold plan | 41,152 | $0.89 | $0.0M | Form 4 |
| Nov 19, 2025 | Luke EvninDirector | Sold plan | 42,566 | $0.94 | $0.0M | Form 4 |
| Nov 19, 2025 | MPM Oncology Innovations Fund GP LLC10% owner | Sold plan | 66,324 | $0.94 | $0.1M | Form 4 |
| Nov 18, 2025 | Luke EvninDirector | Sold plan | 33,776 | $0.93 | $0.0M | Form 4 |
| Nov 18, 2025 | MPM Oncology Innovations Fund GP LLC10% owner | Sold plan | 52,627 | $0.93 | $0.0M | Form 4 |
| Nov 17, 2025 | Luke EvninDirector | Sold plan | 36,621 | $0.95 | $0.0M | Form 4 |
| Nov 17, 2025 | MPM Oncology Innovations Fund GP LLC10% owner | Sold plan | 57,061 | $0.95 | $0.1M | Form 4 |
| Nov 14, 2025 | Luke EvninDirector | Sold plan | 39,560 | $0.93 | $0.0M | Form 4 |
| Nov 14, 2025 | MPM Oncology Innovations Fund GP LLC10% owner | Sold plan | 61,640 | $0.93 | $0.1M | Form 4 |
| Nov 13, 2025 | Luke EvninDirector | Sold plan | 58,372 | $0.98 | $0.1M | Form 4 |
| Nov 13, 2025 | MPM Oncology Innovations Fund GP LLC10% owner | Sold plan | 90,951 | $0.98 | $0.1M | Form 4 |
| Nov 12, 2025 | Luke EvninDirector | Sold plan | 26,101 | $1.09 | $0.0M | Form 4 |
| Nov 12, 2025 | MPM BioVentures 2014, L.P.10% owner | Sold plan | 40,669 | $1.09 | $0.0M | Form 4 |
| Nov 11, 2025 | Luke EvninDirector | Sold plan | 35,818 | $1.14 | $0.0M | Form 4 |
| Nov 11, 2025 | MPM BioVentures 2014, L.P.10% owner | Sold plan | 55,810 | $1.14 | $0.1M | Form 4 |
| Nov 10, 2025 | Luke EvninDirector | Sold plan | 31,172 | $1.18 | $0.0M | Form 4 |
| Nov 10, 2025 | MPM BioVentures 2014, L.P.10% owner | Sold plan | 48,570 | $1.18 | $0.1M | Form 4 |
| Nov 7, 2025 | Luke EvninDirector | Sold plan | 43,950 | $1.11 | $0.0M | Form 4 |
| Nov 7, 2025 | MPM BioVentures 2014, L.P.10% owner | Sold plan | 68,480 | $1.11 | $0.1M | Form 4 |
| Nov 6, 2025 | Luke EvninDirector | Sold plan | 34,947 | $1.21 | $0.0M | Form 4 |
| Nov 6, 2025 | MPM BioImpact LLC10% owner | Sold plan | 54,452 | $1.21 | $0.1M | Form 4 |
| Nov 5, 2025 | Luke EvninDirector | Sold plan | 30,774 | $1.22 | $0.0M | Form 4 |
| Nov 5, 2025 | MPM BioImpact LLC10% owner | Sold plan | 47,950 | $1.22 | $0.1M | Form 4 |
| Nov 4, 2025 | Luke EvninDirector | Sold plan | 90,164 | $1.22 | $0.1M | Form 4 |
| Nov 4, 2025 | MPM BioImpact LLC10% owner | Sold plan | 140,488 | $1.22 | $0.2M | Form 4 |
| Nov 3, 2025 | Luke EvninDirector | Sold plan | 60,369 | $1.29 | $0.1M | Form 4 |
| Nov 3, 2025 | MPM Oncology Innovations Fund LP10% owner | Sold plan | 94,063 | $1.29 | $0.1M | Form 4 |
| Oct 31, 2025 | Luke EvninDirector | Sold plan | 73,192 | $1.28 | $0.1M | Form 4 |
| Oct 31, 2025 | MPM Oncology Innovations Fund LP10% owner | Sold plan | 114,044 | $1.28 | $0.1M | Form 4 |
| Oct 30, 2025 | Luke EvninDirector | Sold plan | 55,795 | $1.43 | $0.1M | Form 4 |
| Oct 30, 2025 | MPM Oncology Innovations Fund LP10% owner | Sold plan | 86,936 | $1.43 | $0.1M | Form 4 |
| Oct 29, 2025 | Luke EvninDirector | Sold plan | 86,154 | $1.55 | $0.1M | Form 4 |
| Oct 29, 2025 | UBS Oncology Impact Fund L.P.10% owner | Sold plan | 134,240 | $1.55 | $0.2M | Form 4 |
| Oct 28, 2025 | Luke EvninDirector | Sold plan | 44,327 | $1.64 | $0.1M | Form 4 |
| Oct 28, 2025 | UBS Oncology Impact Fund L.P.10% owner | Sold plan | 69,068 | $1.64 | $0.1M | Form 4 |
| Oct 27, 2025 | Luke EvninDirector | Sold plan | 46,664 | $1.72 | $0.1M | Form 4 |
| Oct 27, 2025 | UBS Oncology Impact Fund L.P.10% owner | Sold plan | 72,709 | $1.72 | $0.1M | Form 4 |
Financial health
Can it carry its debts, and how well does it use its money?
Balance sheet
KIRA Β· Werewolf Therapeutics, Inc. has $25.0M more cash than debt.
Cash, debt and the ratios that show how comfortably Werewolf Therapeutics, Inc. can carry it.
In plain words: What the company owns and what it owes. More cash than debt is a cushion for bad times; a lot of debt leaves less room when business slows down.
Cash vs debt (incl. leases)
FY20
Cash $92.6M
Debt β
FY21
Cash $158M
Debt β
FY22
Cash $129M
Debt β
FY23
Cash $134M
Debt $40.0M
FY24
Cash $111M
Debt $32.1M
FY25
Cash $57.1M
Debt $32.1M
Cash
Debt
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | $158M | $129M | $134M | $111M | $57.1M |
| Debt incl. finance leases | β | β | $40.0M | $32.1M | $32.1M |
| Debt / equity | β | β | 0.4x | 0.4x | 1.3x |
| Interest coverage | β | β | β12.9x | β15.8x | β11.5x |
| Current ratio | 13.6x | 5.8x | 7.1x | 7.4x | 1.6x |
| Quick ratio | 13.6x | 5.8x | 7.1x | 7.4x | 1.6x |
| Total assets | $179M | $160M | $175M | $127M | $69.4M |
| Total liabilities | $26.5M | $37.9M | $63.5M | $53.5M | $44.6M |
| Shareholders' equity | $153M | $122M | $111M | $73.4M | $24.8M |
| Net debt (β = net cash) | β | β | β$94.3M | β$78.9M | β$25.0M |
Returns on capital
After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
In plain words: How much profit the business makes on the money put into it. A higher percentage means each dollar invested works harder.
Return on capital, equity and assets (annual)
FY20
Return on capital β
Return on equity β
Return on assets β15.6%
FY21
Return on capital β
Return on equity β99.1%
Return on assets β36.3%
FY22
Return on capital β
Return on equity β39.1%
Return on assets β31.7%
FY23
Return on capital β187.9%
Return on equity β32.0%
Return on assets β22.3%
FY24
Return on capital β
Return on equity β76.3%
Return on assets β46.7%
FY25
Return on capital β
Return on equity β123.9%
Return on assets β62.0%
Return on capital
Return on equity
Return on assets
Piotroski F-score
KIRA Β· Werewolf Therapeutics, Inc. passes 1 of 7 financial health tests (Piotroski F-score).
Nine pass/fail tests of profitability, funding and efficiency. 8β9 is strong, 0β2 weak.
In plain words: Nine yes/no tests of financial health, one point each. A green tick is a pass: 7 to 9 points is solid, 0 to 3 is weak.
| Test | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|
| Net income is positive | β | β | β | β | β | β |
| Cash from operations is positive | β | β | β | β | β | β |
| Return on assets rose | β | β | β | β | β | β |
| Cash from operations exceeds net income | β | β | β | β | β | β |
| Debt fell relative to assets | β | β | β | β | β | β |
| Current ratio rose | β | β | β | β | β | β |
| Share count didn't rise | β | β | β | β | β | β |
| Gross margin rose | β | β | β | β | β | β |
| Revenue rose relative to assets | β | β | β | β | β | β |
| F-score | β / 3 | β / 6 | β / 6 | β / 6 | 2 / 7 | 1 / 7 |
| Accruals ratio | 3.7% | β5.2% | β7.8% | β2.8% | β9.5% | β0.5% |
| Altman Z'' | β4.94 | 5.05 | β0.44 | β1.66 | β8.05 | β25.50 |
All figures
Every number, year by year.
6 years of figures
Amounts in USD. Hover a ratioβs name for its definition.
In plain words: Every number we have, year by year. Download it as a spreadsheet if you want to dig deeper.
| Fiscal year | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|
| Income statement | ||||||
| Research and development | $16.6M | $35.3M | $53.8M | $41.8M | $56.4M | $44.8M |
| Operating income | β$22.4M | β$50.1M | β$56.1M | β$40.5M | β$73.6M | β$60.7M |
| Interest expense | β | β | $0.0M | $3.1M | $4.7M | $5.3M |
| Income tax | β | β | β | β | β | $0.0M |
| Net income | β$15.0M | β$50.0M | β$53.8M | β$37.4M | β$70.5M | β$60.8M |
| Net income to common | β$28.2M | β$202M | β$53.8M | β$37.4M | β$70.5M | β$60.8M |
| Diluted EPS | β$28.08 | β$10.94 | β$1.86 | β$1.05 | β$1.63 | β$1.33 |
| Diluted shares | 0.00B | 0.02B | 0.03B | 0.04B | 0.04B | 0.05B |
| Cash flow | ||||||
| Cash from operations | β$18.6M | β$42.9M | β$40.6M | β$32.6M | β$56.2M | β$60.3M |
| Capital expenditure | $0.6M | $0.5M | $3.6M | $0.8M | $0.3M | $0.0M |
| Free cash flow | β$19.2M | β$43.4M | β$44.2M | β$33.4M | β$56.4M | β$60.3M |
| Depreciation and amortization | $0.2M | $0.2M | $1.1M | $1.8M | $1.8M | $1.6M |
| Stock-based compensation | $0.6M | $4.1M | $7.4M | $8.0M | $8.8M | $6.2M |
| Balance sheet | ||||||
| Cash and short-term investments | $92.6M | $158M | $129M | $134M | $111M | $57.1M |
| Total debt | β | β | β | $40.0M | $32.1M | $32.1M |
| Current assets | $92.9M | $161M | $140M | $138M | $113M | $58.6M |
| Current liabilities | $5.3M | $11.9M | $24.0M | $19.4M | $15.2M | $36.1M |
| Property and equipment, net | $0.7M | $2.9M | $9.0M | $8.0M | $6.3M | $4.7M |
| Total assets | $96.4M | $179M | $160M | $175M | $127M | $69.4M |
| Total liabilities | $7.2M | $26.5M | $37.9M | $63.5M | $53.5M | $44.6M |
| Preferred stock | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M |
| Shareholders' equity | β$51.9M | $153M | $122M | $111M | $73.4M | $24.8M |
| Returns | ||||||
| Return on capital | β | β | β | β187.9% | β | β |
| Return on capital employed | β24.6% | β29.9% | β41.1% | β26.1% | β65.9% | β182.5% |
| Return on equity | β | β99.1% | β39.1% | β32.0% | β76.3% | β123.9% |
| Return on assets | β15.6% | β36.3% | β31.7% | β22.3% | β46.7% | β62.0% |
| Return on tangible equity | β | β132.2% | β44.0% | β33.6% | β96.1% | β245.2% |
| Growth | ||||||
| Share count change | β | 1,736.3% | 56.4% | 23.5% | 23.0% | 6.7% |
| Financial health | ||||||
| Debt / equity | β | β | β | 0.4x | 0.4x | 1.3x |
| Interest coverage | β | β | β | β12.9x | β15.8x | β11.5x |
| Current ratio | 17.6x | 13.6x | 5.8x | 7.1x | 7.4x | 1.6x |
| Quick ratio | 17.6x | 13.6x | 5.8x | 7.1x | 7.4x | 1.6x |
| Quality scores | ||||||
| Piotroski F-score | β | β | β | β | 2.0 | 1.0 |
| Altman Z'' | β4.9 | 5.0 | β0.4 | β1.7 | β8.0 | β25.5 |
| Accruals ratio | 3.7% | β5.2% | β7.8% | β2.8% | β9.5% | β0.5% |
Source: SEC EDGAR XBRL filings (CIK 0001785530). Data updated October 24, 2026. Quarterly fourth quarters are the full year minus the first nine months. For information only β not investment advice. Check the original filings before relying on any figure.